UNCY · Unicycive Therapeutics, Inc.
$5.49
+0.06 (+1.10%)
At close · Aug 27
Market Cap
$151.25M
Shares
27.86M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$675K
-29%
FY2023
Net Income
-$26.56M
+27.7%
FY2025
Operating Margin
-3077.63%
-1179.4pp
FY2023
Diluted EPS
-$1.67
+70.4%
FY2025
Operating Cash Flow
-$31.32M
-9.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | — | $675K | $951K | — | — | |
| $9.6M | $9.12M | $20.01M | $12.9M | $12.44M | $6.08M | $1.02M | |
| $23.55M | $20.4M | $12.1M | $8.55M | $6.57M | $2.9M | $1.01M | |
| $701K | — | — | — | $383K | $245K | $58K | |
| — | — | — | — | $428K | $468K | — | |
| $33.14M | $29.52M | $32.12M | $21.45M | $19M | $8.98M | $2.02M | |
| -$33.14M | -$29.52M | -$32.12M | -$20.77M | -$18.05M | -$8.98M | -$2.02M | |
| — | — | — | -3077.63% | -1898.21% | — | — | |
| — | — | — | — | -$17.62M | -$8.51M | — | |
| — | $71K | $71K | $82K | $6000 | $628K | $244K | |
| $1.47M | $1.01M | $1.26M | $615K | — | — | — | |
| -$2.08M | $2.96M | -$4.61M | -$9.77M | -$6000 | -$1.04M | -$244K | |
| -$35.22M | -$26.56M | -$36.73M | -$30.54M | -$18.06M | -$10.02M | -$2.26M | |
| — | — | — | -4525.04% | -1898.84% | — | — | |
| -$35.16M | -$26.56M | -$37.82M | -$31.41M | -$18.06M | -$10.02M | — | |
| — | -$26.56M | -$36.73M | — | — | — | — | |
| USD/shares | -$1.79 | -$1.67 | -$5.65 | -$12.80 | -$12.00 | -$8.60 | -$2.70 |
| USD/shares | -$1.25 | -$1.67 | -$5.65 | -$12.80 | -$12.00 | -$8.60 | — |
| shares | — | 15.89M | 6.7M | 2.45M | 1.51M | 1.17M | 849.97K |
| shares | — | 15.89M | 6.7M | 2.45M | 1.51M | 1.17M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $2M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.62×
EV/EBIT
—
Peer median 11.76×
P/E (TTM)
—
Peer median 10.33×
Peer medians compare against the 301 similar-size Biotechnology companies (of 517 listed).
Key facts
CIK
1766140
CUSIP
90466Y202
13F (30d)
77 filings
75 filers
Visit website
Investor relations